A boy suffering from T-cell acute lymphoblastic leukemia will now be able to undergo a bone marrow transplant at Sheba Medical Center after the GlaxoSmithKline pharmaceutical company flew over a drug as yet unavailable in Israel.
The drug, called Arranon (Nelarabine), is registered in the US but not yet by the Health Ministry. When the Israeli branch of the company heard of the case, he agreed to have the drug supplied to the child free, and also not to charge for the transportation expenses over the weekend.
His condition after two treatments has improved "significantly," according to Dr. Amos Toren, the Sheba pediatric oncologist who is treating him and will soon perform the bone marrow transplant. "We continue to hope that he will be cured."
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>